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Abstract 
 A defective mucosal barrier function is the principal cause of the uncontrolled onset  and progression of a number of 
human inflammatory gut diseases, most of which are characterized by chronic intermittent immune and inflammatory 
responses leading to structural intestinal damage, which can represent a potential risk for colorectal cancer 
development. 
During the active disease phase the production of pro-inflammatory cytokines and chemokines, and the induction of 
oxidative reactions by activated leukocytes and epithelial cells represent  the main event in intestinal inflammation. 
Oxidative stress plays a key role in the development of intestinal damage. Indeed reactive oxygen species and their 
oxidized by-products regulate redox-sensitive signaling pathways and transcription factors, which sustain inflammation 
within the intestinal layer.  
Polyunsaturated fatty acids and cholesterol are the principal targets of oxidative modifications. These lipids, which are 
cell membrane constituents or are present in food, readily undergo non-enzymatic oxidation to form chemically-reactive 
species  that can induce a wide range of biological effects including inflammation, programmed cell death, and 
proliferation. 
In this review we summarize the current knowledge on the role of lipid oxidation products in regulating  redox 
pathways involved in the pathogenesis of inflammation-related gut diseases.  In particular, lipid peroxidation end 
products such as isoprostanes and aldehydes, and cholesterol oxidation-derived oxysterols are taken into consideration.   
We also discuss the hypothesis that controlling oxidative damage and consequently tissue local over-production of lipid 
oxidation products by using specific antioxidant and anti-inflammatory molecules in the  diet may have clinical and 
therapeutic benefits. 
 
Key words: gut; intestinal bowel disease; acrolein, isoprostanes, 4-hydroxynonenal, malondialdehyde, oxysterols, 
polyphenols 
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Graphical abstract. Oxidative stress-derived lipid oxidation products, LPOs and COPs, are involved in the induction 
and maintenance of an inflammatory microenvironment leading to intestinal damage. 
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1. Introduction 
Gut mucosa is constantly exposed to environmental and dietary antigens. It plays a primary role in the absorption of 
nutrients and in protecting the host against lumen pathogens and xenobiotics, for which a precise balance between pro- 
and anti-inflammatory processes controlled by the immune system is necessary. Inflammation is the locally- occurring 
physiological defense reaction in response to infections and tissue injury; it seeks to restore homeostasis by killing 
pathogens and activating tissue repair processes. The process is usually self-limiting  due to the involvement of 
feedback mechanisms. 
A defective mucosal barrier function is the principal cause of the uncontrolled onset of inflammation involved in the 
pathogenesis of a number of intestinal diseases, including irritable bowel syndrome (IBS) [1], inflammatory bowel 
disease (IBD) [2], and pauchitis [3]. IBD, comprising Crohn’s disease (CD) and ulcerative colitis (UC), are the best-
known intestinal diseases; they are characterized by chronic intermittent immune and inflammatory responses that 
induce alternating active and remission periods of the disease. 
Massive gut infiltration by activated leukocytes followed by the production of a  wide spectrum of oxidants, 
cytokines, chemokines, and eicosanoids is the main feature of these intestinal diseases. Notably, during inflammation a 
condition of oxidative stress is established, due to the excess of reactive oxygen species (ROS), such as O2
.-
, H2O2, NO 
and HOCl. These are generated in IBD by recruited inflammatory cells and mucosa-resident cells as an abnormal 
antimicrobial response. Conversely, ROS and their oxidized by-products regulate redox-sensitive signaling pathways 
and transcription factors, which maintain active inflammation within the intestinal layer, thus damaging gut barrier 
integrity. 
Notably, structural and functional defects of the intestinal barrier, and the establishment of an inflammatory 
response, comprise a precancerous condition from which colorectal cancer (CRC) can develop [4]: many cases of CRC 
show marked activation of the redox-sensitive transcription factor Nuclear Factor B (NF-B). Activation of NF-B via 
ROS generation during inflammation strongly supports carcinogenesis  [5].  
Furthermore, gut contact with microbiota can result in redox signaling, which involves O2
.-
 generation through 
catalytic activities of enterocytic NADPH oxidase 1 (NOX1) and phagocytic NADPH oxidase 2 (NOX2)  enzymes [6]. 
This mechanism might be sufficient to aggravate intestinal inflammation in IBD, in which the NF-B signaling pathway 
is persistently activated by pathogen recognition receptors, namely Toll-like receptors (TLRs) and nucleotide-binding 
oligomerization domain (NOD)-like receptors (NLRs) [2]. In particular, NLRs are actively involved in the response 
against intestinal antigens: they can activate mitogen-activated protein kinases (MAPKs) and NF-B via formation of 
the NOD signalosome platform, or can form pro-caspase-1 inflammasome protein complexes, such as the  nucleotide-
binding oligomerization domain, leucine rich repeat, and pyrin domain containing 1 and 3 (NLRP1 and NLRP3). 
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NLRP3 activity is up-regulated by high concentrations of ROS, produced both through NOX hyper-activation and 
through mitochondria malfunctioning; it is probable that this helps to exaggerate the inflammatory response in the 
intestine [7, 8].  
The principal targets of ROS action are lipids, in particular polyunsaturated fatty acids (PUFAs) and cholesterol, 
which are cell membrane constituents or are exogenously present in food. These lipids readily undergo non-enzymatic 
oxidation to form chemically-reactive carbonyl compounds and hydrocarbons; these induce a wide range of biological 
effects including sustained inflammation, programmed cell death, and proliferation. Further, the enzymatic oxidation of 
membrane PUFAs by cyclooxygenases (COXs) and lipoxygenases (LOXs) gives rise to the well-known inflammatory 
mediators known as eicosanoids [9]. 
It is fundamental to understand where and how lipid oxidation products act on the redox pathways involved in the 
pathogenesis of intestinal diseases characterized by chronic inflammation, in order to develop prognostic and risk-
assessment schemes, and to improve anti-inflammatory strategies. This review reports the most relevant findings 
concerning the influence of lipid oxidation products in modulating intestinal inflammation, and highlights the 
importance of diet in maintaining redox balance, which is an emerging field for gut disease research. 
 
2. PUFA-derived oxidation products and their prevalence in intestinal inflammation 
PUFAs are essential fatty acids obtained only from food. Of the unsaturated lipids, the 6-PUFAs arachidonic acid 
(AA) and linoleic acid (LA) are required in humans because they are constituents of phospholipid membranes, and play 
significant roles in cellular membrane fluidity and enzyme activities. The high concentration of PUFAs incorporated in 
phospholipid membranes makes them prime targets for reactions with oxidizing agents. They provide the main substrate 
for enzymatic and non-enzymatic oxidative reactions.  
AA and LA become major targets of ROS attack which initiates lipid peroxidation as a mechanism of lipid chain 
cleavage. Of note, AA undergoes oxidation more readily than LA, because of the greater availability of bisallylic 
positions susceptible to ROS attack.  
The lipid peroxidation chain reaction consists of three steps: initiation, propagation, and termination. In the first 
phase, oxidants, for example free radicals, attack lipid carbon-carbon double bond(s), abstracting hydrogen  and 
inserting oxygen. During the propagation phase, the resulting peroxyl radical intermediates undergo further cyclization, 
oxido-reduction, and/or fragmentation, leading to the formation of more chemically stable end-products. Cyclization 
reactions of peroxyl radicals are responsible for the generation of different sets of isoprostanes (IsoPs). The most 
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important biologically-significant IsoPs formed non-enzymatically are the F2-isoprostanes (F2-IsoPs), which derive 
from AA auto-oxidation [10]. 
Conversely, -scission of lipid hydroperoxide C-C bonds yields a broad array of smaller fragments, three to nine 
carbons in length, mainly grouped as 2-alkenals, ketoaldehydes and 4-hydroxy-2-alkenals [11, 12]. Among aldehydes 
produced as end-products of lipid peroxidation, acrolein, malondialdehyde (MDA) and 4-hydroxynonenal (HNE) are 
the carbonyl compounds most widely studied, due to their strong activity towards cell macromolecules, which may 
result in redox imbalance and inflammation, impairing the mucosal barrier.  
Figure 1 shows the chemical structures of the main PUFAs and of their non-enzymatically oxidized  derivatives of 
biological significance in inflammatory intestinal diseases.  
AA is the main substrate for COX activity; this gives rise to eicosanoids including prostaglandins (PGs) such as 
PGE2, which are involved in the inflammatory response, promoting chemotaxis and activity of phagocytes. Increased 
activity of the inducible COX-2 is considered to be a parameter of inflammation, both in colitis and in colitis-associated 
cancer [13]. 
 
Figure 1. Structures of the main oxysterols derived from cholesterol oxidation.  
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2.1 Isoprostanes 
F2-IsoPs have been extensively studied as markers of oxidative stress in human disease, as attested to by numerous 
papers, extensively reviewed by Milne and co-workers [10]. These compounds have been called prostaglandin-like, 
because they possess the characteristic F-ring of prostaglandins F2 . They are generated independently of the 
cyclooxygenase enzyme, and have been detected in tissues, blood, and urine. They have been shown to increase in 
plasma and urine samples in a number of cardiovascular, pulmonary and neurological diseases that are correlated to 
oxidative stress [14]. However, very few studies have evaluated F2-IsoPs production as a marker of intestinal 
inflammation in animal models [15-19].  F2-IsoPs, together with 11-dehydro-thromboxane B2, have been found 
elevated in the urine of patients with active IBD; the parameters decreased after anti-Tumor Necrosis Factor  (TNF) 
therapy with infliximab in responder IBD patients [20]. Conversely, a study in pediatric IBD patients showed 
inconsistent evidence of inflammation and low levels of F2-IsoPs in exhaled breath condensate samples [21]. 
 
2.2 Acrolein 
Acrolein is the most reactive 2-alkenal commonly detected in  pollution, burning of fat-containing foods, and 
smoking. It is thus mainly considered to be an environmental pollutant,  exposure to which by inhalation induces severe 
irritating effects on mucous membranes, especially in the eyes and upper respiratory tract [22]. However, acrolein can 
also be produced endogenously by lipid peroxidation. Due to its strong electrophilic activity it has been considered 
genotoxic; it acts by inducing acrolein-deoxyguanosine (Acr-dG) DNA adducts, as well as protein adducts associated 
with carcinogenesis [23, 24].  
Acrolein has been shown to be differentially distributed in colon adenomas and in CRC depending on tumor 
degree, and has been associated with transition from benign to malignant colon tumors [25]. A tenfold increase in Acr-
dG  has been detected in CRC cells after silencing aldo-keto reductase 1B10, whose function is to protect cells from 
carbonyl damage by  converting ,-unsaturated carbonyl compounds into less-toxic alcoholic forms [26].  
Conversely, the formation of Acr-dG has been found to correlate with the number of double bonds in PUFAs: thus 
they are mainly produced from -3 docosahexaenoic acid (DHA) and eicosapentaenoic acid, and to a lesser extent from 
AA and LA. HT-29 human colon cancer cells treated with acrolein showed increased Acr-dG levels and augmented 
apoptosis; in parallel, the same cells treated with DHA showed increased Acr-dG levels correlated with the induction of 
apoptosis. This evidence suggests that cell production of acrolein, with increased Acr-dG levels, is a possible 
mechanism whereby DHA might induce apoptosis, and consequently protect against colon tumorigenesis [27].  
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The bioactive derivative of acrolein, cinnamaldehyde, is indeed known for its antiproliferative and pro-apoptotic 
effects, and is now considered as having anticancer properties consisting in modulating cell signaling pathways: for 
instance, it inhibits survival PI3K/Akt signaling in a number of CRC cells [28] and activates cytoprotective antioxidant 
response in human epithelial colon cells by inducing Nuclear Factor-Erythroid 2-Related Factor 2 (NRF2) [29].  
 
2.3 MDA 
Malondialdehyde (MDA) is the most abundant small-chain ketoaldehyde produced by lipid peroxidation, and is 
among the most common parameters used to detect oxidative stress. It is  typically quantified by a colorimetric assay 
based on the reaction between MDA and thiobarbituric acid to form thiobarbituric acid (TBA) reactive substances 
(TBARS) in human fluids. The assay is employed in a number of diseases characterized by inflammation, including 
intestinal diseases. 
Increased MDA tissue levels have been detected in inflamed colonic tissues induced in rodents [30-33], by the 
administration of dextran sodium sulfate (DSS) in mice, or trinitrobenzene sulfonic acid (TNBS) in rats. These two 
chemicals are commonly employed in inducing experimental colitis [34, 35].  
MDA is also routinely used in clinical studies as a lipid peroxidation marker; its level has been evaluated in colonic 
tissues and in plasma from IBD patients. Plasma MDA levels did not differ between IBD patients and normal subjects 
[36, 37]. Conversely, more recent studies have reported a positive correlation between MDA and disease severity, 
suggesting a role for oxidative stress in the development and worsening of inflammation in IBD. MDA has been  shown 
to be elevated in CD patients, and to be the best CD predictor, alongside C reactive protein increase during 
inflammation [38]. Increased MDA levels, associated with acute inflammation, and a marked increase in NOX1 
expression, were evidenced in fresh colon tissues of mice in which colitis had been induced by TNF treatment [39]. 
In another study, both active and remission CD patients showed a significant increase in MDA plasma 
concentration compared to healthy subjects; MDA was significantly lower in inactive than that in active disease. In the 
same study, levels of 8-hydroxy-2’-deoxyguanosine (8-OHdG), which is considered a marker of DNA oxidative 
damage, were permanently elevated in both active and inactive CD patients, reinforcing the hypothesis of IBD as a 
precancerous disease [40]. The inhibition of mitochondrial potential that has been observed in active CD suggests that 
dysfunctional mitochondria may be a major site of the ROS overproduction associated with mucosal damage in IBD 
[40, 41].  Contrasting results reporting levels of oxidative stress in terms of MDA production might be due to the 
different methods and instruments used: a variety of substances other than MDA are also reactive toward TBA, thus 
affecting method specificity. The sensitivity of the assay has increased in recent years thanks to combined use of more 
sophisticated new-generation instruments, such as HPLC or Gas Chromatography/Mass Spectrometry (GC/MS) [42]. 
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2.4 HNE 
Among 4-hydroxy-2-alkenals, 4-hydroxy-2-nonenal (HNE) has been recognized as an important lipid molecule of 
pathophysiological interest. The human plasma concentration of free F2-IsoP is of nanomolar order, while HNE ranges 
from nanomolar to micromolar levels [11]. In particular, the normal HNE concentration in human tissues and plasma 
has been estimated to be in the range  0.05 - 5 M, while in oxidative-damage-related diseases its concentration can be 
as high as 100 M or above. This aldehyde can be measured by specific assays including HPLC and GC/MS or 
immuno-chemical analyses [43-45]. 
HNE levels in different organs, as well as those of other lipid oxidation products, may also be influenced by diet 
[46-48]. For instance, the digestive tract is frequently the first target of dietary compounds containing carbonyl 
compounds. In particular, Larsson and colleagues demonstrated that aldehyde levels are higher in the intestinal lumen 
than it was in meals containing cod liver oil, fish or fish oil, suggesting the gastrointestinal tract may be involved in 
promoting dietary lipid oxidation during digestion. Intestinal cells may thus for several hours be exposed to the action 
of elevated amounts of reactive aldehydes derived from food [49].  
Because of its strong electrophilic character, HNE forms chemical adducts with DNA, proteins, and amine-
containing lipids; the most important chemical reactions are Michael additions and Schiff base formation. Its 
amphiphilic property and relatively long half-life makes it a candidate for the propagation of action distant from the 
production site, to other cells, where it tends to quickly react with macromolecules [43].  
Proteins are quantitatively the most important group of biomolecules targeted by HNE; the resulting stable protein-
adducts are readily detectable by using antibodies that specifically recognize the HNE-histidine epitope [44, 50, 51].  
The wide range of effects produced by HNE depend on the concentration reached in cells or tissues.  High HNE 
levels can exert deleterious events, including cytotoxicity, while at low concentrations HNE may be considered as a 
second messenger of free radical-mediated reactions that modulate important cell functions, such as enzyme activities, 
cell signal transduction, and gene expression [43, 52].  
HNE’s involvement in the pathogenesis of certain human diseases characterized by the marked activation of 
inflammatory processes has been established unequivocally [43, 52, 53]. Increased HNE levels have been found in the 
intestinal mucosa and in the plasma of CD patients [54].  
The primary involvement of HNE in cytotoxicity is related to its metabolism, in particular its conjugation with 
glutathione catalyzed by glutathione-S-transferase, making the aldehyde less toxic/genotoxic. However, this process 
affects the antioxidant defenses: for instance, increased levels of HNE and MDA, together with a decrease in both 
reduced glutathione (GSH) content and SOD/CAT antioxidant enzymes, have been detected in inflamed mucosa from 
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colitic mice, in which inflammation was experimentally induced by DSS or TNBS [55, 56]. CRC cells showing low 
levels of glutathione-S-transferase have been found to be more susceptible to HNE treatment in terms of increased DNA 
damage [57]. Notably, increased levels of HNE-modified DNA bases have been found in the inflamed colon mucosa of 
patients suffering from CD, UC, and chronic pancreatitis [58]. Increased formation of HNE-protein adducts has also 
been found to be inversely associated with antioxidant defenses in human colon cancer tissues [59].  
Low HNE cell concentrations  (1 to 10 M) have been found to inhibit c-myc and p21 gene expression and 
telomerase activity in colon cancer cell lines [60, 61]. HNE-dependent induction of antioxidant adaptive response 
molecules, such as p382 and thioredoxin reductase 1, has been hypothesized as a mechanistic event that protects 
transformed cancer cells, defending them from further exposure to unfavorable oxidative stressors [62]. Further, HNE 
has been considered for a role in colon cancer aggressiveness, for its ability to interact with c-Jun N-terminal kinase 
(JNK) and Smads transducers, favoring the expansion of Transforming Growth Factor-1 resistant intestinal neoplastic 
cell clones [63, 64].  
It is undoubted that HNE acts as a cell growth modulator; it is involved in cell proliferation, survival, apoptosis, 
and differentiation, especially by activating mitogen-activated protein kinases (mainly JNK), phosphoinositide-3-kinase, 
the catalytic alpha polypeptide (PIK3CA)-AKT pathways, and protein kinase C. However, it must be considered that 
the action of this aldehyde is very complex, depending on cell type and concentration [52]. As far as intestinal damage 
is concerned, HNE has been shown to affect intestinal barrier permeability, which is considered one of the main events 
occurring in both IBD and CRC development [65]. The high levels of HNE found in the intestinal mucosa in different 
experimental models of animal colitis have been associated with its ability to alter TLR-4/NF-B inflammatory 
pathway-dependent immune response [55, 66]. 
Although conclusive proof of the involvement of HNE in the pathogenesis of inflammatory intestinal diseases, 
and possibly also that of other aldehydes, including MDA and acrolein, has yet to be obtained, there is no doubt that 
HNE is a very likely candidate molecule for the role of triggering and sustaining a wide range of biochemical events 
underliying the development of these processes. 
 
3. Cholesterol-derived oxidation products and their prevalence in intestinal inflammation 
In a state of oxidative stress, cholesterol is another lipid compound susceptible to ROS attack. As a 
consequence of oxidative modifications, it gives rise to an extensive series of molecules, termed oxysterols, which are 
recognized to possess several effects of physiopathologic relevance. 
3.1 Oxysterols origin  
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Autoxidation primarily occurs on the sterol nucleus at position 7, or at the 5,6 double bond, and generates, among 
others, 7-ketocholesterol (7-K), 7-hydroxycholesterol (7-OH), 5,6- and 5,6-epoxycholesterol (-EPOX and -
EPOX), and cholestan-3,5,6-triol (TRIOL) (Figure 2) [67-69]. 
Other oxysterols also originate endogenously by the enzymatic action of specific cytochrome P450-dependent or -
independent hydroxylases, which yield the side-chain oxidized compounds 22-hydroxycholesterol (22-OH), 24-
hydroxycholesterol (24-OH) (also known as cerebrosterol), 25-hydroxycholesterol (25-OH) and 27-hydroxycholesterol 
(27-OH) [11], but also 7-hydroxycholesterol (7-OH) [67-70] (Figure 2).  
Cholesterol-rich food contains particularly high levels of oxysterols: these compounds originate in vivo in animals 
from both enzymatic and non-enzymatic reactions, and  their content is further enhanced when food is exposed to heat, 
light, air and radiation during cooking, processing, and prolonged storage. The principal oxysterols detected in food are 
7-OH, 7-OH, 7-K, 5,6-EPOX, 5,6- EPOX and TRIOL (Figure 2), commonly present as a mixture; together 
they account for 1-10% of the total cholesterol present in a meal, or even more [71]. Dietary oxysterols are absorbed 
completely in the bowel, cleared from the plasma lipoproteins, and taken up by different tissues and cells, where they 
are transformed through many cholesterol metabolic pathways. This wide variability in the metabolic fate of oxysterols 
makes it difficult to estimate their actual intake [70-72].  
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Figure 2. Structures of the major PUFA-derived oxidation products. 
3.2 Oxysterols’ biological effects 
Oxysterols participate in many physiological processes, most of which are connected to cholesterol metabolism, 
including the biosynthesis of bile acids and the reverse cholesterol transport, but they also participate to steroidogenesis 
and vitamin D synthesis [68-70, 73-76].   
Moreover, the addition of a carbonyl, hydroxyl, or epoxide moiety on the cholesterol structure alters its 3-
dimensional shape and lipid packing, and enhances its hydrophilicity. It follows that oxysterols perturb the fluidity and 
permeability of the biomembranes where they insert, and are able to affect the activity of membrane-bound enzymes 
[76]. They can also pass through lipophilic membranes more easily than can cholesterol, and are redistributed more 
efficiently into the cells [77, 78], where they act as potent molecular regulators [69, 79]. 
For all these reasons, oxysterols are now considered to be important mediators of cholesterol-induced effects 
exerting pro-oxidant, pro-inflammatory, and pro-apoptotic activities, which link them to the pathogenesis of major 
chronic diseases including gut diseases [72, 79, 80]. 
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Like other lipid peroxidation products, it is now demonstrated that cholesterol oxidation products promote and 
sustain inflammatory events, by inducing both the expression and synthesis of several cytokines, interleukins, and 
adhesion molecules; this probably involves redox-sensitive signaling pathways and factors, e.g. NF-B, AP-1 and 
MAPKs [80].  
Of note, it has recently been shown that 7K is able to influence the behavior of macrophages, specifically by 
enhancing the M1 macrophage pro-inflammatory phenotype, and switching M2 macrophages to an intermediate 
phenotype characterized by increased production of pro-inflammatory mediators [81]. This has been reported for 
differentiated human peripheral blood monocytes, but the finding also supports the role of oxysterols as possible 
modulators of innate immune cells.     
Differential proteome changes have also been induced in intestinal CaCo-2 cells after 7K-incubation: such 
incubation significantly increased the expression of several proteins implicated  in lipid homeostasis, vesicle trafficking, 
fatty acid metabolism, mitochondrial membrane composition, immunosurveillance and cell proliferation [82]. 
The evidence that an oxysterol mixture stemming from the heating of dietary cholesterol exerts pro-inflammatory 
effects on human CaCo-2 enterocytes is in accordance with the hypothesis of a possible key role of oxysterols even in 
bowel inflammation; among the oxysterols present in the mixture, 7-OH was the most effective [83]. In these cells the 
oxysterol-induced inflammation was confirmed to be mediated by NF-B-MAPK signaling pathways [84]. Conversely, 
a previous study showed that 25-OH but not 7-OH significantly enhanced IL-8 mRNA expression and synthesis in 
CaCo-2 cells stimulated with IL-1 [85].  
Conversely, oxysterols derived from oxidative modification on the cholesterol side-chain  are natural ligands of 
liver X receptor (LXR), a nuclear factor that has been related to the regulation of inflammatory processes [72, 76, 86].  
The LXR agonist 22(R)-OH inhibited TNF expression in LPS-stimulated human colonic epithelial cells [87]. 
This evidence is in agreement with the anti-inflammatory effects demonstrated in primary macrophages for 22(R)-OH 
and for the other natural LXR ligands 24-OH and 24(S),25-epoxycholesterol [88]. Overall the findings appear to 
indicate that endogenous oxysterols, not present at significant levels in food, specifically act differently than do species 
arising from food cholesterol auto-oxidation; they could thus be employed as therapeutic strategies against bowel 
diseases.   
 
Another way in which oxysterols may contribute to sustaining inflammation-related gut diseases is by altering the 
properties of the intestinal epithelium. It was recently observed that 7K not only reversed IL-10-expression induced in 
CaCo-2 cells by dendritic cells in co-cultures, but also diminished the transepithelial electrical resistance, a parameter 
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reflecting CaCo-2 cell monolayer integrity. This finding is consistent with a down-regulation of tight junction protein 
zonula occludens-1 in CaCo-2 cells. In the same model, 7K also decreased IL-10 induction in dendritic cells; thus the 
overall data suggest that 7K may impair the epithelial barrier, enhance the availability of antigens to the mucosal 
immune system including lamina propria DCs, and thus alter the inflammatory response in the gut mucosa [89]. 
 
Of note, major dietary oxysterols have been shown to possess marked cytotoxicity and to exert pro-apoptotic 
activity towards different cell types and tissues, including intestinal epithelial cells [90]; they might thereby 
compromise epithelial barrier integrity and function. Pro-apoptotic activity, in terms of caspase-3 and caspase-7 
activation, was elicited by 7-OH, 7-OH and -EPOX, but not by a mixture of the three, when administered to 
undifferentiated CaCo-2 cells, suggesting an antitumoral role of specific cytotoxic oxysterols [91]. Conversely, an 
oxysterol mixture triggered the mitochondrial apoptotic pathway in differentiated colonic cells, but not in 
undifferentiated ones [92]. 
 
 Analysis of the mechanisms underlying oxysterol-induced damage in greater depth points to ROS overproduction 
and oxidative stress exacerbation as the main event leading to gut injury. For example, increased ROS levels leading to 
mitochondrial perturbation and apoptosis were reported for CaCo-2 cells exposed to 7-OH [93]. In the same cells the 
observed interleukin over-expression and apoptotic response appeared to be triggered by oxysterols through NOX1 
activation and consequent intracellular ROS steady-state increase [83, 84, 91, 92].  
Oxysterols might indirectly contribute to inflammatory and cell death processes by favoring the synthesis of AA, 
which is the precursor of eicosanoids and of several lipoperoxidation products of pathological relevance (see above). 
Indeed, an increase in the activity of 6-desaturase, a key enzyme in the conversion of LA to AA, has been found in rats 
fed an oxysterol enriched diet [94-96]. 
 
Oxysterols may also display their pathological activity through inflammasome activation, as recently reported for 
different cell types. 7-Ketocholesterol appeared to favor microglia cell activation and polarization to a pro-inflammatory 
M1 state via NLRP3 activation [97]. Furthermore, the same oxysterol stimulated inflammasome formation in bone 
marrow-derived cells, leading to IL-1 production [98]. 7-Ketocholesterol also appeared to induce secretion of the 
processed form of caspase-1 by murine primary macrophages, in an NLRP3 inflammasome dependent manner [99]. 
Notably, 25-OH, which mainly derives from enzymatic reactions, appeared to repress IL-1 activating 
inflammasome in response to Interferon signaling, in activated mouse macrophages [100]. 
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The above findings point to the interactions between oxysterols and inflammasome complexes as a possible cause 
of gut inflammation, even if data are still lacking. In the light of the pro-oxidant properties of oxysterols and of the 
inflammasome signaling dependence on ROS [101, 102], investigations into their interplay might provide new insights 
into the development of bowel diseases. 
 
3.3 Potential oxysterol and bile acid partnership in intestinal disease 
Lastly, an interesting new perspective concerning the possible role of cholesterol oxidation products in bowel 
disease etiopathology may arise from considering their connection with bile acids (BAs). Some of the main oxysterols 
are, indeed,  formed as intermediates of classical or “alternative” BA biosynthetic pathways (i.e. 7-OH, 27-OH and 
3-hydroxy-5-cholestenoic acid), while oxysterols of extra-hepatic origin can be transported to the liver, where they 
also are metabolized into BAs [72, 103, 104]. Some oxysterols, indeed, appear to be substrates for sterol 27-
hydroxylase, which is the first enzyme of the “alternative” pathway of BA synthesis, highly expressed in liver and 
macrophages [69, 70].  
Because of these analogies it may be presumed that oxysterols share at least some of the chemical and biological 
properties that point to BAs as important players in promoting and sustaining bowel inflammation and dysfunction.  
In this connection, BAs appear to enhance colonic fluid and electrolyte secretion, and to impair lipid digestion, 
thus leading to diarrhea and steatorrhea; BAs apparently increase intestinal mucosa permeability, likely as a 
consequence of direct epithelial toxicity or through impairment of the epithelial tight junctions [105, 106].  
It has been observed that continuous exposure of intestinal cells to elevated level of certain hydrophobic BAs is 
correlated with greater susceptibility to colorectal carcinogenesis, mainly as a consequence of oxidative DNA damage 
[107, 108].  
Conversely, beneficial effects have been ascribed to BAs, in particular as promoters of mucosal epithelial integrity 
and modulators of anti-inflammatory responses in immune cells [105, 108].  
Athough the data are somewhat controversial, the oxysterol-dependent regulation of key enzymes of BA 
metabolism has been reported [104]. For example, hepatic microsomal 7-hydroxylase activity can be either inhibited 
or  increased by different oxysterols [109].  
As has already been said, side chain oxidized oxysterols are ligands of LXR, which regulates BA  excretion and 
cholesterol transport by controlling the expression of members of the ATP-binding cassette membrane transporters in 
the intestine and in macrophages [72, 86].  
Taking these findings together, it is reasonable to think that oxysterols, in their turn, may contribute to the 
regulation/impairment of the BA pool in the intestine, thus being  indirect modulators of the effects ascribed to them. 
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Lastly, gut microbiota is fundamental in BA metabolism, since it enzymatically converts primary BAs to 
secondary BAs in the colon [110]. In the case of gut dysbiosis, a feature typical of IBD patients, BA dysmetabolism 
occurs and potentially triggers pro-inflammatory responses in colonic epithelium [105].  
Similarly, although the possibility of oxysterol modification by gut microbiota has not yet been explored, it 
certainly cannot be ruled out. Its  consequence might be the formation of compounds having varying degrees of harmful 
effects which in turn could affect intestinal condition. 
 
4. Possible therapeutic approaches 
Conventional therapy on intestinal inflammatory diseases mainly entails long-term treatment with 5-
aminosalicylates (5-ASA) and corticosteroids as classical anti-inflammatory agents reducing the formation of 
eicosanoids via COX2. More recently, treatments with immunomodulators and biological agents have been  accepted in 
order to reduce immune system hyper-responsiveness in IBD patients with inadequate response to the standard 
treatment with 5-ASA and steroids. The use of anti-TNF antibody is now considered as the mainstream treatment for 
improving mucosal healing and these patients’ quality of life [111, 112]. However, duration or discontinuation of anti-
TNF therapy associated with important side effects with risk of relapse is still debated [113]. 
Interestingly, the potential mechanism of action attributed to 5-ASA as ROS/RNS scavenger [114, 115] supports 
the hypothesis of the important role of oxidative stress in intestinal inflammatory diseases.  
Recent developments in molecular medicine point to design a proper supplementation with antioxidants that can 
target selective molecules involved in redox signaling, as well as with specific lipids able to increase cell antioxidant 
response, induce anti-inflammatory derivatives, and diminish the formation of lipid oxidation end products.  Modulating 
NF-B signaling and targeting ROS overproduction sites, such as plasma-membrane NOX and mitochondria, may 
provide promising therapeutic options to decrease intestinal damage [2, 116].  
The importance of the maintenance of high antioxidant intestinal levels comes from experimental animal models of 
colitis, in which the improvement of colonic mucosa damage was observed after administration of GSH or its precursor 
N-acetylcysteine (NAC) [117, 118]. GSH supplementation significantly prevented lipid peroxidation associated with 
improved tissue damage [117]. 
IL-1 release and caspase-1 activity, which are closely related to NLRP3 activation in experimental DSS-induced 
colitis, were significantly decreased in murine peritoneal macrophages  by MAPK kinase inhibitors, and NAC [119].  
In this perspective, special nutritional regimens counteracting or preventing intestinal inflammation could be 
considered. For instance, a comprehensive mixture of aminoacids and vitamins A, C, and E are employed in parenteral 
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nutrition, a commonly used procedure in patients with gastrointestinal disorders in order to maintain adequate 
nutritional status. Supplemental antioxidant vitamins added to enteral feeding solutions have been reported to 
ameliorate disease severity in critically ill patients associated with a resistance to oxidative stress measured in plasma in 
terms of TBARs and low density lipoprotein oxidation [120]. 
During disease remission the resolution of acute inflammation requires a temporal switch from pro- to anti-
inflammatory eicosanoids, and their fatty acid precursors. Lymphocytes and macrophages can contribute to resolve 
inflammation through endogenous generation of specific 3- and 6-PUFA derivatives with anti-inflammatory and 
pro-resolving activity. Among these products, resolvins and protectins derive from the degradation of 3-PUFAs, and 
are potent bioactive compounds that exert their anti-inflammatory function by blocking trans-endothelial leukocyte 
migration and infiltration [121]. The administration  of exogenous resolvin E1 protects against colitis development in 
mice by reducing leukocyte peritoneal infiltration and increasing survival and histological scores. The reduction of NF-
B phosphorylation and expression, together with a decrease in TNF, IL-1, and IL-6 were also observed [122, 123]. 
Resolvins are also generated after 5-ASA treatment because they are formed by aspirin-dependent acetylated form of 
COX2. Systemic treatment with aspirin-triggered resolvins D1 and D2, or 17-hydroxy-DHA D1-precursor was 
demonstrated to improve disease activity index and reduce colonic cytokines and adhesion molecules levels, as well as 
NF-B expression in mice models of colitis [124]. This evidence provides a basis for understanding a novel mechanism 
of action of both non-steroidal anti-inflammatory drugs and dietary 3-PUFA supplementation counteracting intestinal 
inflammation. Therefore, dietary supplementation with 3-PUFAs may be promising in minimizing or preventing 
inflammatory diseases because of their potential action as substrates for anti-inflammatory eicosanoids’ production. 
However, there are not enough data proving their beneficial effects, and there is still no consensus on 3-dietary 
recommendations for IBD patients [125]. 
Dietary supplementation with polyphenols has recently attracted much attention as an alternative natural 
approach to prevent or treat chronic inflammatory diseases because of their strong antioxidant and anti-inflammatory 
properties. Polyphenols are a heterogeneous group of plant secondary metabolites that can be introduced with the diet. 
Therefore, they reach their highest concentration in the gut, where they can exert their peak of activity. Solid 
experimental proofs in intestinal cells as well in animal models of colitis showed a marked ability of polyphenols in 
reducing intestinal injury by modulating inflammatory and immune responses [33, 112]. For instance, quercetin has 
been found to improve intestinal barrier function by enhancing the expression of claudin-4 tight junction protein in 
intestinal CaCo-2 cells [126]. Polyphenols present in wine, as well as in green tea, were able to modulate intestinal 
inflammation induced by dietary oxysterols in enterocyte-like cells by suppressing pro-inflammatory cytokine 
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formation [83, 127]. Numerous signals appear to be regulated by these compounds. NOX1 and p38 MAPK activities 
have been shown to be negatively regulated by specific polyphenols present in wine. The down-stream transcriptional 
factor mainly involved in the cellular regulation by polyphenols appears to be NF-B [84]. Polyphenols also show 
prebiotic activity by inhibiting the growth of detrimental bacteria and stimulating beneficial bacteria such as 
Lactobacteria and Bifidobacteria in the gut [128, 129]. 
Despite several studies on experimental models, epidemiological trials suggesting a positive association 
between fruit/vegetable consumption and human intestinal inflammation are still limited [130]. 
 
5. CONCLUSIONS 
This review has examined the current understanding on the emerging molecular role of lipid oxidation products 
in the pathogenesis of inflammatory intestinal diseases.  
Special emphasis was given to the detrimental role played by IsoPs, acrolein, MDA and HNE produced during 
membranes lipid peroxidation, as well as oxysterols generated by cholesterol oxidation during inflammation-associated 
redox changes. 
Most of these molecules have shown to be reliable biomarkers of oxidative stress because of their high levels in 
biological fluids and intestinal tissue. Therefore, they could represent  an important prognostic value in the evaluation of 
the different stages of inflammatory diseases.  
The clinical significance of oxidative stress in IBD is now becoming clear, and may soon lead to new therapeutic 
options to ameliorate intestinal damage in this disease. 
As a consequence, nutritional regimens with specific antioxidants and anti-inflammatory compounds could 
counteract or at least prevent gut disease development or progression. 
 
 
LIST OF ABBREVIATIONS  
22-OH: 22-hydroxycholesterol; 
24-OH: 24-hydroxycholesterol;  
25-OH: 25-hydroxycholesterol;  
27-OH: 27-hydroxycholesterol;  
5-ASA: 5-aminosalicylates;  
7-K: 7-ketocholesterol;  
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7-OH: 7-hydroxycholesterol;  
7 -OH: 7-hydroxycholesterol; 
 8-OHdG: 8-hydroxy-2'-deoxyguanosine; 
AA: arachidonic acid;  
Acr-dG: acrolein-deoxyguanosine;  
Akt: protein kinase B;  
AP-1: activator protein-1;  
BA: bile acid; 
CD: Crohn’s disease;  
COX: ciclooxygenase;  
CRC: colorectal cancer;  
DHA: docosahexaenoic acid; 
DSS: dextran sulfate sodium;  
ERK: extracellular signal-regulated kinase;  
GC/MS: Gas Chromatography/Mass Spectrometry; 
GSH: glutathione;  
HNE: 4-hydroxynonenal;  
HNE-dG: HNE-deoxyguanosine;  
HO-1: heme oxygenase-1;  
HPLC: High Performance Liquid Chromatography; 
IBD: inflammatory bowel disease;  
IL: interleukin;  
IsoPs: isoprostanes; 
JNK: c-Jun N-terminal kinase; 
LA: linoleic acid; 
LOX: lipooxygenase;  
LT: leukotriene;  
LXR: liver X receptor; 
MAPK: mitogen activated protein kinase;  
MDA:  malondialdehyde;   
NAC: N-acetylcysteine;  
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NADPH: nicotinamide adenine dinucleotide phosphate;  
NF-B: nuclear factor-B;  
NLRP1: NLR family pyrin domain containing 1;  
NLRP3: NLR family pyrin domain containing 3;  
NLRs: NOD-like receptors; 
NOD: nucleotide-binding oligomerization domain; 
NOX: NADPH oxidase;  
NRF2: nuclear factor-erythroid 2-related facyor 2;  
p38: protein 38;  
PGs: prostaglandins;  
PI3K: phosphoinositide 3-kinase; 
PUFA: polyunsaturated fatty acid;  
RNS: reactive nitrogen species;  
ROS: reactive oxygen species;  
TBA: thiobarbituric acid;  
TBARS: TBA reactive substances;  
TNBS: 2,4,6-trinitrobenzene sulfonic acid;  
TNF: tumor necrosis factor;  
TRIOL: cholestan-3,5,6-triol; 
TRL: toll like receptor;  
UC: ulcerative colitis;  
-EPOX: 5,6-epoxycholesterol;  
-EPOX: 5,6-epoxycholesterol. 
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Figure Legends 
Figure 1. Structures of the main oxysterols derived from cholesterol oxidation.  
 
Figure 2. Structures of the major PUFA-derived oxidation products. 
Graphical abstract. Oxidative stress-derived lipid oxidation products, LPOs and COPs, are involved in the induction 
and maintenance of an inflammatory microenvironment leading to intestinal damage. 
 
 
